Health Care & Life Sciences » Pharmaceuticals | Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
637
684
989
426
601
825
Total Accounts Receivable
125
186
210
234
224
264
Inventories
29
30
19
34
43
53
Other Current Assets
75
115
40
54
100
93
Total Current Assets
865
1,016
1,258
748
968
1,234
Net Property, Plant & Equipment
14
58
86
107
170
200
Intangible Assets
1,263
2,140
1,843
3,906
3,927
3,659
Other Assets
22
49
16
24
24
46
Total Assets
2,238
3,339
3,333
4,800
5,124
5,203
ST Debt & Current Portion LT Debt
6
9
38
36
41
Accounts Payable
21
25
22
22
24
Income Tax Payable
7
17
2
5
22
Other Current Liabilities
171
165
165
194
207
Total Current Liabilities
204
217
227
257
294
Long-Term Debt
544
1,333
1,151
1,994
1,540
Deferred Taxes
94
300
153
542
349
Other Liabilities
26
43
73
115
193
Total Liabilities
943
1,968
1,734
2,923
2,411
Common Equity (Total)
1,295
1,371
1,599
1,877
2,713
Total Shareholders' Equity
1,296
1,371
1,599
1,877
2,713
Total Equity
1,296
1,371
1,599
1,877
2,713
Liabilities & Shareholders' Equity
2,238
3,339
3,333
4,800
5,124
Accumulated Minority Interest
-
-
-
-
-
Preferred Stock (Carrying Value)
-
-
-
-
-

About Jazz Pharmaceuticals

View Profile
Address
Waterloo Exchange
Dublin Dublin 4
Ireland
Employees -
Website http://www.jazzpharma.com
Updated 07/08/2019
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C.